Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis

INTRODUCTION: Lixisenatide is a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus (T2DM). Its efficacy and safety have been assessed in a series of phase 3 studies included in the GetGoal program. In these studies, lixisenatide was found to be superior to placebo in glycemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Hua, Gu, Li-na, Men, Li-chuang, Lu, Ju-ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118245/
https://www.ncbi.nlm.nih.gov/pubmed/27796905
http://dx.doi.org/10.1007/s13300-016-0207-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118245/
https://www.ncbi.nlm.nih.gov/pubmed/27796905
http://dx.doi.org/10.1007/s13300-016-0207-6

Ejemplares similares